These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 7938559

  • 1. An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).
    Cutler NR, Sramek JJ, Macpherson AE, Doss MG, Benes CO, Howard SF.
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):685-94. PubMed ID: 7938559
    [Abstract] [Full Text] [Related]

  • 2. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group.
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [Abstract] [Full Text] [Related]

  • 3. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
    Cutler NR, Sramek JJ, Keppel Hesselink JM, Krol A, Roeschen J, Rickels K, Schweizer E.
    J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E.
    JAMA; 2000 Jun 21; 283(23):3082-8. PubMed ID: 10865302
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study.
    Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher JP, Sermet E, Servant D.
    J Clin Psychiatry; 2002 Nov 21; 63(11):1020-7. PubMed ID: 12444816
    [Abstract] [Full Text] [Related]

  • 6. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
    Cutler NR, Sramek JJ, Wardle TS, Hesselink JM, Roeschen JK.
    Psychopharmacol Bull; 1993 Nov 21; 29(2):303-8. PubMed ID: 7904761
    [Abstract] [Full Text] [Related]

  • 7. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
    Hirschfeld RM, Weisler RH, Raines SR, Macfadden W, BOLDER Study Group.
    J Clin Psychiatry; 2006 Mar 21; 67(3):355-62. PubMed ID: 16649820
    [Abstract] [Full Text] [Related]

  • 8. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
    Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC.
    Arch Gen Psychiatry; 2005 Sep 21; 62(9):1022-30. PubMed ID: 16143734
    [Abstract] [Full Text] [Related]

  • 9. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.
    Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, Wisselink PG, Greiner M, Pierce MW, Pande AC.
    J Clin Psychopharmacol; 1995 Dec 21; 15(6):428-34. PubMed ID: 8748432
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
    Davidson JR, DuPont RL, Hedges D, Haskins JT.
    J Clin Psychiatry; 1999 Aug 21; 60(8):528-35. PubMed ID: 10485635
    [Abstract] [Full Text] [Related]

  • 11. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.
    Katz IR, Reynolds CF, Alexopoulos GS, Hackett D.
    J Am Geriatr Soc; 2002 Jan 21; 50(1):18-25. PubMed ID: 12028242
    [Abstract] [Full Text] [Related]

  • 12. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G, Beeské S, Stahl SM.
    J Clin Psychiatry; 2012 Nov 21; 73(11):1403-11. PubMed ID: 23146246
    [Abstract] [Full Text] [Related]

  • 13. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
    Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV.
    Eur Neuropsychopharmacol; 2012 Dec 21; 22(12):847-57. PubMed ID: 22898365
    [Abstract] [Full Text] [Related]

  • 14. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.
    Mezhebovsky I, Mägi K, She F, Datto C, Eriksson H.
    Int J Geriatr Psychiatry; 2013 Jun 21; 28(6):615-25. PubMed ID: 23070803
    [Abstract] [Full Text] [Related]

  • 15. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study.
    Nimatoudis I, Zissis NP, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G.
    Int Clin Psychopharmacol; 2004 Nov 21; 19(6):331-6. PubMed ID: 15486518
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study.
    Merideth C, Cutler AJ, She F, Eriksson H.
    Int Clin Psychopharmacol; 2012 Jan 21; 27(1):40-54. PubMed ID: 22045039
    [Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
    Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y.
    Hum Psychopharmacol; 2014 Jan 21; 29(1):64-72. PubMed ID: 24424707
    [Abstract] [Full Text] [Related]

  • 18. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE, Franznick DA, Hollander SB, Fava M.
    J Clin Psychiatry; 2004 Aug 21; 65(8):1069-75. PubMed ID: 15323591
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder.
    Montgomery SA, Locklear JC, Svedsäter H, Eriksson H.
    Int Clin Psychopharmacol; 2014 Sep 21; 29(5):252-62. PubMed ID: 24394383
    [Abstract] [Full Text] [Related]

  • 20. A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder.
    Czobor P, Skolnick P, Beer B, Lippa A.
    CNS Neurosci Ther; 2010 Apr 21; 16(2):63-75. PubMed ID: 20041911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.